| abstract |
The present invention provides patients with bronchial epithelial infection with 90-130 mg of aminoglycoside antibiotics as a dry powder aerosol composition to the patient's bronchial system one day during the first treatment period of 20-36 days. Provides treatment by administration ˜3 times. According to an aspect of the present invention, a second treatment cessation period can be provided after the first treatment period during which no aminoglycoside antibiotic is administered to the patient's bronchial system. For the treatment of malignant infections, the first treatment phase with aminoglycoside antibiotic administration to the patient's bronchial system and the subsequent second treatment cessation cycle without administration of aminoglycoside antibiotics, antibacterial effect Can be repeated two or more times until appears. In the case of a chronic infection, such as an infection that affects a CF patient, this first and second treatment cycle can be repeated multiple times during patient treatment. |